Stanleick Andrew Roy
Known title: Chief Executive OfficerCIK: 0001909193
Stanleick Andrew Roy's purchase track record
Stanleick Andrew Roy has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/17/2023 | SKIN | $100K | -69.2% | -43.6% | +15.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SKIN | ▲ Buy | Open Market | 16,485 | $100K | 8/17/2023 | View on chart |
| SKIN | ▲ Buy | Grant | 294,579 | — | 4/5/2023 | View on chart |
| SKIN | ▲ Buy | Grant | 58,536 | — | 3/1/2023 | View on chart |
| SKIN | ▲ Buy | Grant | 333,333 | — | 2/7/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
SkinHealth Systems Expands SkinStylus MicroSystem to Europe
SkinHealth Systems announced that its SkinStylus® SteriLock® MicroSystem will now be available in European markets. The move expands the company’s footprint beyond North America and could broaden its customer base. The product is a sterilization platform used in dermatology. The news comes as the stock trades near its 52‑week low, but the expansion may support future growth.
SkinHealth Systems Expands SkinStylus MicroSystem to Europe. SkinHealth Systems announced that its SkinStylus® SteriLock® MicroSystem will now be available in European markets. The move expands the company’s footprint beyond North America and could broaden its customer base. The product is a sterilization platform used in dermatology. The news comes as the stock trades near its 52‑week low, but the expansion may support future growth.